alphalisa hiblock buffer (Revvity)
Structured Review

Alphalisa Hiblock Buffer, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alphalisa+buffer/AlphaLISA+HiBlock+Buffer%2C+10X/pmc09424863-307-6-9
Average 91 stars, based on 6 article reviews
Images
1) Product Images from "Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies"
Article Title: Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies
Journal: Molecular Therapy. Nucleic Acids
doi: 10.1016/j.omtn.2022.07.027
Figure Legend Snippet: ASO-001933 is a highly potent and selective ASO targeting MAPT on human neurons (A) Schematic diagram of ASO treatment schedule in hESCs for (B)–(F). (B) Dose-dependent reduction of MAPT expression at RNA and protein level upon ASO-001933 or BIIB080 treatment. hESC-derived neurons were treated with ASO at indicated concentrations. RNA and protein levels were assessed by qRT-PCR and AlphaLISA respectively. Absolute IC 50 values are reported in the figure (n = 3 /treatment, mean +/- SEM). (C) Quantification of 3R and 4R Tau mRNA by qPCR after ASO treatment at 1 μM (n = 3 /treatment, mean +/- SEM). (D and E) Representative images of RNAscope ISH and ICC using probes against MAPT CDS, MAPT 3′ UTR (D) and antibody against Tau (Tau HT7) (E). (F) Volcano plot illustrating differentially regulated proteins from proteomics analysis between ASO-001933-treated cells versus NT ASO-treated neurons (n = 3). MAPT is the only significantly regulated protein (Log2 FC = −2.94, adjusted Log10 p value = −4.54). (G) Evaluation of off-target effects of ASO-001933 in hiPSC-derived neurons. Volcano plot showing differentially expressed genes (Log2FC > 1 or Log2FC< −1 and −Log10 adjusted p >20) from RNA-seq analysis after 72 h of treatment (n = 3).
Techniques Used: Expressing, Derivative Assay, Quantitative RT-PCR, RNA Sequencing Assay
Related Articles
Incubation:Article Title: β-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer’s Disease Article Snippet: An extensive fluorine scan of 1,3-oxazines revealed the power of fluorine(s) to lower the pKa and thereby dramatically change the pharmacological profile of this class of BACE1 inhibitors.. The CF3 substituted oxazine 89, a potent and highly brain penetrant BACE1 inhibitor, was able to reduce significantly CSF Aβ40 & 42 in rats at oral doses as low as 1 mg/kg.. The effect was long lasting, showing a significant reduction of Aβ40 & 42 even after 24 h. In contrast to 89, compound 1b lacking the CF3 group was virtually inactive in vivo. Article Title: Tau Protein Modulates an Epigenetic Mechanism of Cellular Senescence Article Snippet: Cell lysates were treated with benzonase (707463, Novagen) for 15 min at 37°C, centrifuged at 20’000 g for 10 min at 4°C and supernatants were collected as cell extracts. .. These latter were diluted in Protein Concentration:Article Title: Decreased striatal adenosine A 2A -dopamine D 2 receptor heteromerization in schizophrenia Article Snippet: PVDF membranes were washed with PBS-T three times (5 min each) before incubation with either a horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (1/30,000; Pierce Biotechnology, Rockford, IL, USA), HRP-conjugated rabbit anti-goat IgG (1/10,000; Pierce Biotechnology) or HRP-conjugated rabbit anti-guinea pig IgG (1/3,000; Pierce Biotechnology) in blocking solution at 20 °C during 2 h. After washing the PVDF membranes with PBS-T three times (5 min each), the immunoreactive bands were developed using a chemiluminescent detection kit (Thermo Fisher Scientific, Waltham, MA, USA) and were detected with an Amersham Imager 600 (GE Healthcare Europe GmbH, Barcelona, Spain). .. Mouse striatal and human caudate membranes were homogenized in Generated:Article Title: Quantifiable analysis of cellular pathway inhibition of a Nedd8-activating enzyme inhibitor, MLN4924, using AlphaScreen. Article Snippet: 0003-2697/$ see front matter 2013 Elsevier Inc. All rights reserved. http://dx.doi.org/10.1016/j.ab.2013.04.016 ⇑ Corresponding author.. Fax: +1 617 551 7919.. E-mail address: michael.bembenek@mpi.com (M.E. Recombinant:Article Title: Quantifiable analysis of cellular pathway inhibition of a Nedd8-activating enzyme inhibitor, MLN4924, using AlphaScreen. Article Snippet: 0003-2697/$ see front matter 2013 Elsevier Inc. All rights reserved. http://dx.doi.org/10.1016/j.ab.2013.04.016 ⇑ Corresponding author.. Fax: +1 617 551 7919.. E-mail address: michael.bembenek@mpi.com (M.E. Protease Inhibitor:Article Title: Quantifiable analysis of cellular pathway inhibition of a Nedd8-activating enzyme inhibitor, MLN4924, using AlphaScreen. Article Snippet: 0003-2697/$ see front matter 2013 Elsevier Inc. All rights reserved. http://dx.doi.org/10.1016/j.ab.2013.04.016 ⇑ Corresponding author.. Fax: +1 617 551 7919.. E-mail address: michael.bembenek@mpi.com (M.E. |

